Abstract
Background. Inhibition of fibroblast growth factor receptor type 2 (FGFR2) appears to be appropriate in patients with tumors expressing or amplifying FGFR2. The toxicity of allosteric FGFR2 inhibitors has not been previously studied. Purpose. Evaluation of the toxicity of the anticancer drug alofanib (RPT835), allosteric inhibitor of fibroblast growth factor receptor 2 type (FGFR2), in standard experimental in-vivo models in rodents and non-rodents. Material and methods . The general toxic effect of the alofanib was studied in an acute and chronic experiment on outbred animals (rats and rabbits) of both sexes. An experimental study was conducted in accordance with the ethical principles of handling laboratory animals. Results. The assumption that inhibition of FGFR2 provides a low level of toxicity has been proved. It was established that alofanib belongs to the 4 class of low-toxic chemical substances according to the classification of hazard levels of toxic effects of drugs and to the low-risk drugs by the value of the index of the therapeutic action, as well as to the 3 class (low-toxic drugs) according to the class of hazards for clinical application. Alofanib doesn»t cause allergenic and immunotoxic effects as well as doesn»t have pyrogenic properties. Increase of phosphates level (class-specific adverse effect of FGFR2 inhibitors) was statistically significant but less evident. During the study was noticed such an adverse effect as inhibition of spermatogenesis. Conclusion. Alofanib belongs to the classes of low-hazard and low-toxic chemicals and can be studied in a clinical study.
Highlights
Inhibition of fibroblast growth factor receptor type 2 (FGFR2) appears to be appropriate in patients with tumors expressing or amplifying FGFR2
An experimental study was conducted in accordance with the ethical principles
The assumption that inhibition of FGFR2 provides a low level of toxicity has been proved
Summary
Оценка токсичности противоопухолевого препарата алофаниб (RPT835), аллостерического ингибитора рецептора фактора роста фибробластов 2 типа (ФРФР2), в стандартных экспериментальных моделях in vivo на грызунах и негрызунах. Одним из направлений разработки препаратов такого типа является блокирование рецептора, которое приводит к практически полному торможению роста опухоли, что было доказано в экспериментальных моделях. В экспери‐ ментах по изучению специфической фармакологической активности препарата показано, что он избирательно бло‐ кирует специфические участки рецептора фактора роста фибробластов 2 типа, подавляя рост злокачественных опухолей. При введении первой дозы препарата, эквивалентной терапевтической, большинство семенных канальцев крыс оказались пусты, элементы сперматогенеза не классифи‐ цировались, можно было выделить измененные спермато‐ гонии первого порядка и сперматоциты Описанные выше результаты экспериментального ис‐ следования по изучению влияния препарата на систему иммунитета позволили заключить, что препарат алофаниб не обладает иммунотоксическими и аллергизирующими свойствами, а выявленные изменения носят транзиторный характер.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.